[HTML][HTML] Levodopa-induced dyskinesias in Parkinson's disease: An overview on pathophysiology, clinical manifestations, therapy management strategies and future …
L di Biase, PM Pecoraro, SP Carbone… - Journal of clinical …, 2023 - mdpi.com
Since its first introduction, levodopa has become the cornerstone for the treatment of
Parkinson's disease and remains the leading therapeutic choice for motor control therapy so …
Parkinson's disease and remains the leading therapeutic choice for motor control therapy so …
New insights into the mechanism of drug-induced dyskinesia
AJM Loonen, SA Ivanova - CNS spectrums, 2013 - cambridge.org
Dyskinesia is an extrapyramidal movement disorder characterized by involuntary, repetitive,
irregular motions that affect the mouth and face and/or the limbs and trunk. Tardive …
irregular motions that affect the mouth and face and/or the limbs and trunk. Tardive …
[HTML][HTML] Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
EG Poltavskaya, OY Fedorenko, EG Kornetova… - Life, 2021 - mdpi.com
Background: Schizophrenia is a complex mental disorder with a high heritability.
Dysfunction of the N-methyl-D-aspartate (NMDA)-type glutamate receptors may be involved …
Dysfunction of the N-methyl-D-aspartate (NMDA)-type glutamate receptors may be involved …
[HTML][HTML] Putative role of immune reactions in the mechanism of tardive dyskinesia
AJM Loonen - Brain, Behavior, & Immunity-Health, 2023 - Elsevier
The term extrapyramidal disorders is most often used for conditions such as Parkinson's
disease or Huntington's disease, but also refers to a group of extrapyramidal side effects of …
disease or Huntington's disease, but also refers to a group of extrapyramidal side effects of …
Genetics and treatment response in Parkinson's disease: an update on pharmacogenetic studies
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by a
progressive loss of dopamine neurons of the central nervous system. The disease …
progressive loss of dopamine neurons of the central nervous system. The disease …
Genetics of tardive dyskinesia: promising leads and ways forward
Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder
secondary to chronic use of dopamine receptor blocking medications. Genetic factors have …
secondary to chronic use of dopamine receptor blocking medications. Genetic factors have …
Поиск биомаркеров и разработка фармакогенетических подходов к персонализированной терапии больных шизофренией
СА Иванова, ОЮ Федоренко, ЛП Смирнова… - … вестник психиатрии и …, 2013 - elibrary.ru
В статье представлены предварительные результаты исследований в области
трансляционной психиатрии. Основные направления связаны с поиском биомаркеров …
трансляционной психиатрии. Основные направления связаны с поиском биомаркеров …
Pharmacogenetics of tardive dyskinesia: an updated review of the literature
Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term
exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial …
exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial …
From genomics to omics landscapes of Parkinson's disease: revealing the molecular mechanisms
S Redenšek, V Dolžan, T Kunej - Omics: a journal of integrative …, 2018 - liebertpub.com
Molecular mechanisms of Parkinson's disease (PD) have already been investigated in
various different omics landscapes. We reviewed the literature about different omics …
various different omics landscapes. We reviewed the literature about different omics …
New findings in pharmacogenetics of schizophrenia
The findings to date are promising and provide us a better understanding of the
development of side effects and response to antipsychotics. However, more comprehensive …
development of side effects and response to antipsychotics. However, more comprehensive …